Naveris, a healthcare company dedicated to improving patient care through early detection of virus-related cancers, today announced the close of its expanded Series A financing, bringing the total raised to over $19 million since the company’s inception. Gurnet Point Capital (GPC), a private investment fund focused in the healthcare and life sciences sector, led the financing round.


Naveris, Inc. is a molecular diagnostics company developing and bringing to market novel blood tests to enhance the early detection and clinical management of viral-associated cancers. The company has developed the NavDx® test, which uses proprietary technology to detect tumor tissue modified HPV. For additional information, visit the company’s website https://www.naveris.com.

Naveris, Inc. Raises $19 Million in Financing to Advance and Commercialize Blood Tests for Early Detection of HPV and Other Viral-Related Cancers

Description

Company Information

Funding Insights

Naveris, Inc. Raises $19 Million in Financing to Advance and Commercialize Blood Tests for Early Detection of HPV and Other Viral-Related Cancers

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information